Also known as Sutent
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.Source: Wikipedia
Estimated Total Cost: $5599.52 for an average of 28 days supply
Patients are most commonly prescribed sunitinib to treat kidney cancer, metastatic cancer, blastomycosis, and rabies.